Cardiology

Crisis Point returns with an episode on cardiometabolic health disparities, as 3 experts unravel the scope of the crisis, from its historical basis to ongoing social determinants of health in the modern age.

Using data from more than 8500 patients from a bioimaging study, investigators took a deep dive into potential associations between gut microbiome and subclinical atherosclerosis in adults without a history of cardiovascular disease

Expansions in access by the Centers of Medicare and Medicaid Services could bring the latest advances in continuous glucose monitoring into the hands of millions with diabetes, which could provide significant, population-level impact and bring the field a step closer to equitable diabetes management.

Our latest case report from Brady Pregerson, MD, features an elementary-school-aged boy brought to the emergency department by his mother for chest pain. Check out the ECG and determine the correct diagnosis!

This cardiology case report from Brady Pregerson, MD, features a man in his late 80s presenting to urgent care with multiple episodes of near syncope in the past 3 days. Check out the ECG and determine the correct diagnosis!

After adjusting for potential confounding factors, patients with microvascular diseases, particularly diabetic retinopathy, and diabetic kidney disease, were found to have a greater possibility of left ventricular hypertrophy.

Our June 2023 cardiology month in review includes 3 FDA approvals, a primary prevention subgroup analysis of CLEAR Outcomes, and a meta-analysis of 13 major trials examining SGLT2 inhibitor use.

An analysis of a primary prevention subgroup within the CLEAR Outcomes trial presented at ADA 2023 suggests use of bempedoic acid was associated with a 30% relative risk reduction for MACE among this patient population.

A meta-analysis of 13 trials suggests SGLT2 inhibitors reduced heart failure events and cardiovascular death across these patient populations, with consistent effects in patients with varying disease combinations.

The new scientific statement from the AHA indicates multiple social, economic, and health variables contribute to disparities in the development, diagnosis, and treatment of PAD.

Announced by AGEPHA Pharma US on June 20, 2023, the US FDA approval of colchicine 0.5 mg tablets (Lodoco) for reducing cardiovascular event risk marks the first approval in agency history for an anti-inflammatory atheroprotective cardiovascular treatment.

This cardiology case report from Brady Pregerson, MD, features man in his late-60s presenting to urgent care with 3 days of upper respiratory infection symptoms and one episode of near syncope. Check out the ECG and see if you can determine the correct diagnosis!

A phase 4 trial of men with hypogonadism in the US offers an overview of the potential risk of major cardiovascular events associated with use of testosterone replacement therapy.

On June 15, 2023, Bristol Myers Squibb announced the FDA approved an updated label for mavacamten (Camzyos) to reflect the agent's ability to reduce the need or eligibility for septal reduction therapy in patients with obstructive HCM based on VALOR-HCM.

Research presented at ENDO 2023 suggests a high number of adults in the United States with normal BMI still have obesity.

Among more than 80,000 older adults with T2D and established CVD, those in the highest quartile of out-of-pocket costs were less likely to initiate a GLP-1 R or SGLT2 inhibitor.

New data from the phase 2 ROSE2 trial is providing insight into the safety and tolerability, as well as LDL-lowering effects, of obicetrapib as an adjunct to high-intensity statin therapy as a monotherapy and in combination with ezetimibe.

An analysis of the Dubbo study suggests elevated Lp(a) is an independent and significant predictor of recurrent CHD in older people over a 16-year period.

At the 7th Annual Heart in Diabetes meeting, Joseph discussed the need to advance equity in diabetes management, from clinical practice to community-based interventions.

Stephen Greene, MD, discusses the results of a recent GWTG-HF registry analysis, which concluded just 1 in 5 hospitalized patients with HFrEF were discharged with an SGLT2 inhibitor prescription and less than 10% were receiving all 4 classes of guideline-directed medical therapy.

Steve Greene, MD, discusses the results of a TRANSFORM-HF analysis comparing the effects of furosemide and torsemide on quality of life outcomes in patients with heart failure.

Our latest cardiology case report from Brady Pregerson, MD, features a man in his mid-60s presenting with chest pains and palpitations. Can you determine the correct diganosis?

In recent years, the field of endophenotyping has garnered significant attention in sleep health, signaling a growing recognition of the need to move beyond simplistic measures.

An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.

“How can we use these data to harness the power it has to do a better job of predicting clinical outcomes and looking at treatment responsiveness?” Dr. Reena Mehra asks.

However, results from the Vet-COACH trial reported a significant improvement in mental health–related quality of life in the intervention group compared with the control group.

The possibility that sleep apnea could be one of the unrecognized factors exacerbating the growing rates of AF emphasizes the necessity of awareness, screening, diagnosing, and treating sleep apnea.

An analysis of Medicaid data from adults in Alabama suggests just more than 50% of patients fail to get ambulatory follow-up care within the recommended 14-day window following a first-time heart failure hospitalization.

Improved symptoms in 3 men with heart failure caused by ATTR-CM were confirmed by cardiovascular magnetic resonance scans showing the build-up of amyloid proteins had cleared.

12-month adherence to GLP1-RA or SGLT2i therapies was highest among individuals with T2D and/or heart failure with a low prescription co-payment.